Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Three Firms Sign Up With MPP For Long-Acting Cabotegravir

Aurobindo, Cipla And Viatris’s Mylan Agree Deal To Produce HIV PrEP Treatment

Executive Summary

Three generics firms – Aurobindo, Cipla and Viatris’s Mylan – have signed licensing agreements with the Medicines Patent Pool that will allow them to produce versions of ViiV Healthcare’s long-acting cabotegravir treatment for HIV pre-exposure prophylaxis.

You may also be interested in...

Medicare Weighing National Part B Coverage For ViiV’s HIV PrEP Apretude As ‘Preventive Service’

Unusual national coverage determination for a prevention-only drug was opened in response to a formal request from ViiV for its long-acting injectable.  

ViiV Readies Entry To HIV PrEP Market After Apretude Approval

A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.

Stada Gets FDA Nod For US Epoetin Alfa Supply

Stada has received US FDA approval to supply the Retacrit epoetin alfa biosimilar to partner Pfizer for the US market, allowing it to expand on an existing European supply arrangement.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts